Announcement on the 2019 profit distribution plan.
Release time:
2021-05-20
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Pro 2020-005
Zhejiang Jianfeng Group Co., Ltd.
Announcement on 2019 Profit Distribution Plan
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Content Note:
- Distribution Ratio per Share: Cash Dividend 3.0 Yuan (Tax Included) for Every 10 Shares. No bonus shares will be distributed and no CPF capitalization will be made in 2019.
- This profit distribution is based on the total share capital registered on the equity registration date of the implementation of the equity distribution, and the specific date will be specified in the equity distribution implementation announcement.
- If the total share capital of the company changes before the equity registration date for the implementation of the equity distribution, it is proposed to maintain the distribution ratio per share unchanged and adjust the total distribution accordingly, and the specific adjustment will be announced separately.
- Brief description of this year's profit distribution plan: At present, the company is in the stage of accelerated development. In 2020, the company will accelerate the promotion of Guizhou peak daily production of 4500 tons of cement clinker new dry cement production line off-site technical transformation (with waste heat power generation) project, peak pharmaceutical Jinxi production base annual output of 2 billion pieces of solid preparation project, Anhui Zhongwang phase II technical transformation project, new Beika chemical technical transformation project and other projects under construction. In addition, Spike Pharmaceuticals has a number of new drugs in various stages of research and development, anti-tumor drug "DPT" has entered the clinical stage, the need to increase research and development investment. The development of the above-mentioned business requires large financial support. The content of
1. profit distribution plan
was audited by Tianjian Certified Public Accountants (Special General Partnership). The net profit attributable to the shareholders of the parent company in the consolidated statement of the company in 2019 was ,724,688,055.43 yuan. The net profit of the parent company's accounting statement ,267,306,832.98 yuan. According to the parent company's current net profit as the base, extract 10% statutory provident fund 26,730,683.30 yuan, plus undistributed profit 1,014,878,186.69 yuan at the beginning of the year, minus 2018 annual cash dividend 103,225,148.40 yuan, and the distributable profit for this year is 1,152,229,187.97 yuan.
Company plans to make cash distribution in 2019 , based on ,344,083, 828 shares at the end of 2019 , with cash dividends 3.0 yuan (tax included) for every 10 shares, and the total cash dividends to all shareholders registered on the date of record are 103,225,148.40 yuan (tax included).
No CPF conversion to share capital in 2019 .
If the total share capital of the Company changes due to the conversion of convertible bonds/ repurchase of shares / equity incentive grant of share repurchase and cancellation / major asset restructuring share repurchase and cancellation during the period from the date of disclosure of this announcement to the date of registration of equity distribution, the Company intends to maintain the distribution ratio per share and adjust the total distribution accordingly. If the subsequent total share capital changes, the specific adjustment will be announced separately.
This profit distribution plan still needs to be submitted to the general meeting of shareholders for consideration. During the reporting period of
, the net profit attributable to the shareholders of the listed company in the consolidated statement of the company was 724,688,055.43
yuan, the accumulated undistributed profit of the parent company was1,152,229,187.97 yuan, and the total cash dividend to be distributed by the listed company was 103,225,148.40 yuan (including tax), the proportion of net profit attributable to shareholders of listed companies this year is lower than 30% . The specific reasons are as follows: At present, the company is in the stage of accelerated development and has many construction projects. In 2020
, the company will continue to accelerate the construction of the project( estimated investment is 6.5 .2 billion ) of the new dry cement production line with a daily output of 4500 tons of cement clinker in Guizhou Huangping Jianfeng Cement Co., Ltd; the holding subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. Jinxi Production Base produces 20 .6 billion pieces of solid preparation project ( is expected to invest 50146 million yuan ) ; The holding subsidiary Anhui zhongwang pharmaceutical co., ltd. phase ii technological transformation project ( estimated total investment is 17500 .06 million yuan ) ; the construction and renovation of the technical renovation project ( is expected to invest 13274.25 .12 million yuan ) and other projects under construction by the end of 2019 , the above-mentioned projects have invested 4.91 .8 billion yuan. In addition, Jianfeng Pharmaceutical has a number of new drugs in various stages of research and development. The new anti-tumor drug "DPT " has entered the clinical stage. Jianfeng Pharmaceutical and its subsidiaries Zhejiang Erying Pharmaceutical Co., Ltd. and Zhejiang Jianfeng Yien Biotechnology Co., Ltd. will further increase product research and development and introduction, and need to increase research and development investment. The development of the above-mentioned business requires large financial support. 3. the decision-making procedure performed by the company
(I) the convening, deliberation and voting of the board meeting
2020
April# December August24 , the company held the 14th meeting of the 10th board of 131 by combining on-site and communication voting. the company currently has eight directors, all of whom attended the meeting in person, comply with the relevant provisions of the "Company Law" and the "Articles of Association", and the resolutions made are legal and valid. The meeting was presided over by Chairman Jiang Xiaomeng. After deliberation and voting, the profit distribution plan of the company 2019 was deliberated and approved by 8 votes, 0 votes against, and 0 votes abstention. The board of directors of intends to submit the plan to the annual general meeting of shareholders of 2019 for deliberation. When the company holds the general meeting of shareholders, it will provide investors with convenient conditions for online voting.
(II) Independent Director's OpinionThe independent director of the company expressed the following opinions on the company's 2019
annual profit distribution plan:1
, agreeing that the company will pay a cash dividend of 3.0
yuan (including tax) for every10 shares based on 2019 year-end share capital ,344,083, 828 shares, the total amount of cash dividends distributed to all shareholders registered on the date of record is 103,225,148.40 yuan (including tax), 2019 year will not be converted into share capital. , the profit distribution plan is based on the actual operating results and financial situation of the Company
2019, combined with the actual needs of the Company's future business development. Retained undistributed profits are mainly used to meet the capital needs of the company's development, which is conducive to the sustainable and healthy development of the company, and there is no harm to the rights and interests of shareholders, especially small and medium shareholders. The independent directors are of the opinion that the profit distribution plan complies with the relevant provisions of the Articles of Association for profit distribution and the actual operating conditions of the Company. 3 , the company's board of directors considered and approved the above profit distribution plan. The Independent Directors are of the opinion that the convening, convening and deliberation and voting procedures of this meeting are in compliance with relevant laws, regulations and the Articles of Association of the Company, and are legal and effective; and agree to submit the proposal to the Company's
2019Annual General Meeting for consideration. (III) the opinions of the board of supervisors
2020, the company held the 184 meeting of the 9th 183 of the 9th board of supervisors. the company currently has five supervisors, all of whom attended the meeting in person, which conforms to the relevant provisions of the company law and the articles of association, and the resolution made is legal and effective. The meeting was presided over by Mr. Chen Tianci, Chairman of the Board of Supervisors. After deliberation and voting, the company's profit distribution plan for the year 2019 was deliberated and approved with 5 votes, 0 votes against, and 0 abstentions. Agree to submit to the general meeting of shareholders for consideration. The Board of Supervisors believes that: the company's 2019 profit distribution plan complies with the relevant provisions of the Articles of Association; the description of the profit distribution plan is objective and true, the decision-making procedures are in compliance, and meet the interests of all shareholders and the company's production and operation needs; No company profit distribution and cash dividend decisions were found to damage the legitimate rights and interests of shareholders.
4. Related Risk Reminder This profit distribution plan must be submitted to the company's 2019
annual general meeting for deliberation and approval before implementation. Investors are kindly requested to pay attention to investment risks.hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
April
28, 2002
More information
On the afternoon of June 9, Peak Cable Company organized all employees to learn fire fighting knowledge and conducted fire fighting and emergency escape drills. Since June, the subordinate enterprises of the company have organized training, learning and drills related to production safety according to their own characteristics and combined with the actual work. Safety production month series of activities carried out in an orderly manner.
2022
06-13
Spike Postdoctoral Research Papers on International Frontier Journals
Recently, good news came from the postdoctoral workstation of Jianfeng Pharmaceutical. Under the guidance of workstation mentor Jiang Xiaomeng, associate researcher Yang Xiaoxiao has made new progress in the treatment of alcoholic liver disease. The relevant research results "Roxadustat, a hypoxia-inducible factor 1a activator, attenuates both long- and short-term alcohol induced alcoholic liver disease" were published in the internationally renowned academic journal "Frontiers in Pharmacology. This journal is a frontier journal in the field of international pharmacy, mainly publishing academic papers and information on basic and clinical pharmacology, medicinal chemistry, pharmacology and toxicology.
2022
06-01
Daye Peak QC Achievements Won the Third Prize of Huangshi City
On May 7, Huangshi City Quality Strong City Working Committee organized a 2022 QC Results Conference. The QC project of "Technical Transformation of Ore Limestone Batching System" of Daye Peak Cement Company won the third prize.
2022
06-01
On April 28, Dalian Commodity Exchange held an online working meeting to announce the results of the 2021 excellent delivery warehouse and delivery warehouse excellent futures personnel selection, peak international trading company won the 2021 "excellent designated delivery warehouse" title, futures commissioner Ruan Weihang won the "excellent futures personnel" title.
2022
06-01
Cranberry extract combination identification detection method won the invention patent
After cranberry extract products were included in the "Zhejiang Province Key High-tech Product Development Project Plan" in 2021, Jianfeng Health Technology Company recently obtained an invention patent for the identification and detection method of cranberry extract. This new combined identification and detection method developed by Jianfeng Health identifies whether catechin or procyanidin B2 is added in cranberry extract by thin layer analysis, and then detects the unique A- type procyanidin and its chromatographic distribution in cranberry extract by high performance liquid chromatography, so as to improve the accuracy of product judgment. The identification method has the characteristics of accurate results and short detection time, which is of great significance to standardize the cranberry extract market and promote the healthy development of the industry, and has been unanimously recognized by peers.
2022
05-20
Daye Peak Manufacturing Department Won the Title of "Worker Pioneer" in Hubei Province
A few days ago, the manufacturing department of Daye Peak Cement Company was awarded the title of "Worker Pioneer" by the Hubei Provincial Federation of Trade Unions. Daye Jianfeng Manufacturing Department not only continued to actively explore and achieved good results in energy saving and consumption reduction, technological transformation, product quality process control, and economic responsibility system to guide management, but also improved Daye Jianfeng's overall operation level and won Huangshi City The seventh "Mayor Quality Award" created conditions and was fully affirmed by government departments at all levels.
2022
05-20